Submitted by dcc on Fri, 2017-07-21 08:36 Study Title: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentCIRB: Adult CIRB - Late Phase EmphasisLead Group: SWOGStatus: ActiveReview Status: Available to Open
